Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 3909 Records) |
| Query Trace: Lung Neoplasms and Egfr[original query] |
|---|
| EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment? Anticancer research 2024 12 45 (1): 335-340. Giuseppina Improta, Giulia Vita, Alfredo Tartarone, Giovanni Calice, Ludmila Carmen Omer, Angela Zu |
| Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53. Lung cancer (Amsterdam, Netherlands) 2024 12 199 108068. Mingying Wu, Na Zhou, Mei Guan, Yingyi Wang, Yuzhou Wa |
| Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024 12 . Jii Bum Lee, Su-Jin Choi, Hyo Sup Shim, Byung Jo Park, Chang Young Lee, Sumedha Sudhaman, Sharlene Velichko, Min Hee Hong, Byoung Chul Cho, Sun Min L |
| COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer. The oncologist 2024 12 . Camille Mehlman, Aurelie Swalduz, Isabelle Monnet, Clara Morin, Marie Wislez, Florian Guisier, Hubert Curcio, Pauline Du Rusquec, Alexis B Cortot, Valerie Gounant, Baptiste Abbar, Boris Duchemann, Etienne Giroux-Leprieur, Thomas Pierret, Fleur-Marie Quilot, Jacques Cadranel, Vincent Fall |
| Alternating Administration of Osimertinib for Leptomeningitis and Docetaxel Plus Ramucirumab for Lung Adenocarcinoma Resistant to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Case Report. Internal medicine (Tokyo, Japan) 2024 12 . Haruka Tomizawa, Atsuto Mouri, Satsuki Mikoshiba, Kasumi Tsukamoto, Yukiko Abe, Miku Oda, Maya Tsuchiya, Takashi Yamana, Kozo Suhara, Mitsuhiro Kamimu |
| Optimal intervention timing for craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastases. BMC cancer 2024 12 24 (1): 1571. Guangchuan Deng, Qunxing Zhang, Jing Fan, Chenran Zhao, Hui Jiao, Zhenxiang |
| Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with EGFR-mutated non-small-cell lung cancer: a retrospective, multicenter cohort study. Therapeutic advances in medical oncology 2024 12 16 17588359241303090. Ichidai Tanaka, Kazumi Hori, Junji Koyama, Soei Gen, Masahiro Morise, Yuta Kodama, Akira Matsui, Ayako Miyazawa, Tetsunari Hase, Yoshitaka Hibino, Toshihiko Yokoyama, Tomoki Kimura, Norio Yoshida, Mitsuo Sato, Makoto Ish |
| The prevalence and clinical significance of EGFR mutations in non-small cell lung cancer patients in Egypt: a screening study. Journal of the Egyptian National Cancer Institute 2024 12 36 (1): 39. Asmaa A Helal, Ibrahim H Kamal, Ahmed Osman, Magdy Youssef, Adel K Ibrah |
| Clinical utility and predictive value of cerebrospinal fluid cell-free DNA profiling in non-small cell lung cancer patients with leptomeningeal metastasis. Neoplasia (New York, N.Y.) 2024 12 60 101113. Sheng-Kai Liang, Wei-Yu Liao, Jin-Yuan Shih, Chia-Lin Hsu, Ching-Yao Yang, Shang-Gin Wu, Yen-Ting Lin, Yueh-Feng Wen, Lun-Che Chen, Yen-Fu Chen, Ya-Fang Chen, Yen-Heng Lin, Chong-Jen |
| Outcomes of patients receiving urgent palliative radiotherapy for advanced lung cancer: an observational study. BMC palliative care 2024 12 23 (1): 296. Yang Xu, Celestee Trach, Tracey Tessier, Rishi Sinha, David Skarsga |
| CKAP4 is a potential therapeutic target to overcome resistance to EGFR-TKIs in lung adenocarcinoma. Genes & genomics 2024 12 . Seongeun Song, Sangmyung Rh |
| Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer. Japanese journal of clinical oncology 2024 12 . Tsuyoshi Hirata, Kageaki Watanabe, Yukio Hosomi, Kiyotaka Yoh, Kazuhiro Usui, Kazuma Kishi, Go Naka, Shu Tamano, Kohei Uemura, Hideo Kunit |
| Clinical outcomes of patients with EGFR-mutated NSCLC developing interstitial lung disease during first-line osimertinib therapy: a sub-analysis of the Reiwa study. Japanese journal of clinical oncology 2024 12 . Takayuki Kobayashi, Kageaki Watanabe, Yukio Hosomi, Kiyotaka Yoh, Kazuhiro Usui, Kazuma Kishi, Go Naka, Shu Tamano, Kohei Uemura, Hideo Kunit |
| PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study. Journal of the Formosan Medical Association = Taiwan yi zhi 2024 12 . Ching-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, Kuan-Yu Chen, Tzu-Hsiu Tsai, Chia-Lin Hsu, Kang-Yi Su, Yih-Leong Chang, Chen-Tu Wu, Chia-Chi Hsu, Yi-Nan Liu, Guan-Ru Peng, Almanzo Aeterna Kangartaputra, Shu-Han Yu, Bin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, Chia-Chi Lin, Jin-Yuan Shih, James Chih-Hsin Yang, Chong-Jen |
| Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024 12 . Daniele Tavernari, Maxime Borgeaud, Ximeng Liu, Parikh Kaushal, Xiuning Le, Giovanni Ciriello, Alfredo Add |
| Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA. Investigational new drugs 2025 1 . Yoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, Shun-Ichi Isa, Keiichi Nakamura, Yasuyuki Mizumori, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako, Koji Yamazaki, Masahiro Shimada, Masahiko Ando, Yasuhiro K |
| Comparative analysis of EGFR mutations in circulating tumor DNA and primary tumor tissues from lung cancer patients using BEAMing PCR. Scientific reports 2025 1 15 (1): 1252. Duhita Mirikar, Nandini Banerjee, Kumar Prabhash, Rajiv Kumar Kaushal, Vanita Naronha, C S Pramesh, George Karimundackal, Amit Joshi, Swapnil Rane, Ranjan Bas |
| Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non-Small Cell Lung Cancer: Results of India Cohort. JCO global oncology 2025 1 11 e2400353. Ullas Batra, Kumar Prabhash, Vanita Noronha, Ramakant Deshpande, Sachin Khurana, Gull Mohammad Bhat, Rajesh Mistry, Vivek Agarwala, Sajjan Rajpurohit, Bhavesh Poladia, Mansi Sharma, Saquib Zaffar Band |
| Patients with non?small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review). Oncology letters 2025 1 29 (3): 109. Jia-Yu Liu, Shou-Zheng Wang, Han-Qi Yuan, Jun-Ling Li, Pu-Yuan Xi |
| Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases. Heliyon 2025 1 10 (24): e40703. Liqun Li, Zhe Huang, Yangqian Chen, Hongzhi Ma, Xiaoquan Chen, Huan Yan, Haoyue Qin, Yuda Zhang, Xing Zhang, Wenjuan Jiang, Zhan Wang, Lin Zhang, Fanxu Zeng, Zhiguo Zhou, Xingxiang Pu, Nong Yang, Liang Zeng, Yongchang Zha |
| Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial. The Lancet. Oncology 2025 1 26 (1): 74-84. Yanjun Xu, Kaiyan Chen, Yujin Xu, Hui Li, Zhiyu Huang, Hongyang Lu, Dingzhi Huang, Sizhe Yu, Na Han, Lei Gong, Jing Qin, Jun Chen, Fajun Xie, Wei Hong, Xiao Lin, Fengzhuo Cheng, Xiaojie Luo, Yun F |
| Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2025 1 . Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E Marmarelis, Yuichiro Ohe, Reyes Bernabe Caro, Dong-Wan Kim, Jong-Seok Lee, Sophie Cousin, Eiki Ichihara, Yongsheng Li, Luis Paz-Ares, Akira Ono, Rachel E Sanborn, Naohiro Watanabe, Maria Jose de Miguel, Carole Helissey, Catherine A Shu, Alexander I Spira, Pascale Tomasini, James Chih-Hsin Yang, Yiping Zhang, Enriqueta Felip, Frank Griesinger, Saiama N Waqar, Antonio Calles, Joel W Neal, Christina S Baik, Pasi A Jänne, S Martin Shreeve, Joshua C Curtin, Bharvin Patel, Michael Gormley, Xuesong Lyu, Jun Chen, Pei-Ling Chu, Janine Mahoney, Leonardo Trani, Joshua M Bauml, Meena Thayu, Roland E Knoblauch, Byoung Chul C |
| Comprehensive analysis of genomic alterations and novel prognostic biomarkers, and establishment of prediction models of metastasis in metastatic non-small cell lung cancer. Journal of Cancer 2025 1 16 (1): 339-350. Kangwei Wang, Meifeng Ye, Zexun Mo, Xiaomei Huang, Yujun Li, Shuquan W |
| Comparison of tissue-based and plasma-based testing for EGFR mutation in non-small cell lung cancer patients. Journal of pathology and translational medicine 2025 1 59 (1): 60-67. Yoon Kyung Kang, Dong Hoon Shin, Joon Young Park, Chung Su Hwang, Hyun Jung Lee, Jung Hee Lee, Jee Yeon Kim, JooYoung |
| A Drug-Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer. Clinical pharmacology in drug development 2025 1 . Michael J Hanley, Steven Zhang, Nick Pavlakis, Ross A Soo, Anthonie J van der Wekken, Vinod Ganju, Adela Piña, Qi Dong, Neeraj Gup |
| Non small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor response when treated with afatinib: a case report. Frontiers of medicine 2025 1 . Xiaotong Qiu, Liangkun You, Chongwei Wang, Jin She |
| Brief report: Impact of consolidation durvalumab on unresectable non-small lung cancer with driver mutations. Cancer treatment and research communications 2025 1 42 100863. Jason C S Ho, K M Cheu |
| RET-AREAL: a multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs. Cancer letters 2025 1 217455. Xinjun Tang, Jie Hu, Renhua Guo, Yina Wang, Yu Yao, Liang Zeng, Haitao Wang, Haibo Shen, Jun Chen, Weina Huang, Lihua Liu, Ming Su, Zhuang Yu, Weidong Mao, Jinliang Wang, Haitao Tao, Guilan Dong, Chang Cai, Yupeng Xie, Tao Qu, Yan Zhang, Wei Shen, Jing Cao, Xin Cai, Wencui Kong, Xiaoxue Li, Fei Lia |
| Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study. European journal of cancer (Oxford, England : 1990) 2025 1 217 115224. Hsin-Yi Wang, Wei-Yu Liao, Chao-Chi Ho, Shang-Gin Wu, Ching-Yao Yang, Chia-Lin Hsu, Yen-Ting Lin, James Chih-Hsin Yang, Jin-Yuan Sh |
| Ethnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2025 1 . Francisco Cezar Aquino de Moraes, Anna Luíza Soares de Oliveira Rodrigues, Eric Pasqualotto, Jessica Fernanda Cassemiro, Jhonny Wilson Limachi Choque, Rommel Mario Rodríguez Burba |
- Page last reviewed:Feb 1, 2024
- Content source: